Drug Profile


Alternative Names: Bexagliflozin L-proline; EGT-0001442; EGT-0001474; EGT-1442; THR-1442

Latest Information Update: 14 Dec 2016

Price : $50

At a glance

  • Originator Theracos
  • Class Antihyperglycaemics; Glucosides; Pyrans; Small molecules
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Type 2 diabetes mellitus

Most Recent Events

  • 14 Dec 2016 Theracos initiates enrolment in a phase I drug-drug interaction trial in Healthy volunteers in USA (PO, Tablet) (NCT02956044)
  • 02 Nov 2016 Theracos plans a phase I drug-drug interaction trial in Healthy volunteers in USA (PO, Tablet) (NCT02956044)
  • 01 Sep 2016 Theracos initiates a phase III trial for Type-2 diabetes mellitus in USA and Spain (PO, tablet) (NCT02836873)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top